Initial Management of Hypertension

Diagnosis Confirmation

• The European Society of Cardiology recommends confirming the diagnosis of hypertension through out-of-office blood pressure measurements (ambulatory blood pressure monitoring or home blood pressure monitoring) before starting treatment, especially for patients with blood pressure readings between 140-159/90-99 mmHg 1, 2
• For patients with blood pressure readings between 140-159/90-99 mmHg, the diagnosis should be confirmed using ambulatory blood pressure monitoring or home blood pressure monitoring before initiating treatment, according to the European Heart Journal 1, 2
• If ambulatory or home monitoring is not feasible, multiple measurements should be taken in the clinic on separate visits, as recommended by the European Heart Journal 1, 2
• The diagnosis should be based on at least 2 measurements per visit and 2-3 separate visits, according to the European Heart Journal 3

Initial Evaluation

• The American Heart Association recommends calculating the 10-year cardiovascular risk using the ASCVD calculator in the US or the SCORE in Europe, as part of the initial evaluation of patients with hypertension 4, 5
• The initial evaluation should include laboratory tests such as urinalysis, serum electrolytes, creatinine, blood glucose, and total cholesterol:HDL ratio, as recommended by the European Society of Cardiology 5
• An electrocardiogram should also be performed as part of the initial evaluation, according to the European Society of Cardiology 5

Treatment Decision

• The American College of Cardiology recommends starting non-pharmacological therapy alone for patients with stage 1 hypertension (140-159/90-99 mmHg) and a 10-year cardiovascular risk <10%, without target organ damage or diabetes 4, 5
• For patients with stage 1 hypertension and a 10-year cardiovascular risk ≥10% or target organ damage or diabetes, the American College of Cardiology recommends starting a combination of non-pharmacological and pharmacological therapy simultaneously 4, 5
• The European Society of Cardiology recommends starting immediate combination therapy with non-pharmacological and pharmacological interventions for patients with stage 2 hypertension (≥160/100 mmHg) 4, 5

Non-Pharmacological Interventions

• The American Heart Association recommends lifestyle modifications including sodium restriction (<1500 mg/day), increased potassium intake (3500-5000 mg/day), weight loss if overweight or obese, regular physical activity (90-150 minutes/week), and moderation of alcohol consumption (≤2 drinks/day for men, ≤1 drink/day for women) for all patients with hypertension 5

Pharmacological Treatment

• The American College of Cardiology recommends the following first-line agents for the treatment of hypertension: thiazide diuretics, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers 4, 5
• The European Society of Cardiology recommends preferring ACE inhibitors or angiotensin receptor blockers as initial agents in patients with diabetes or chronic kidney disease 5
• The American College of Cardiology recommends avoiding the combination of ACE inhibitors and angiotensin receptor blockers 4

Monitoring and Follow-Up

• The European Society of Cardiology recommends monitoring electrolytes and renal function 2-4 weeks after initiating ACE inhibitors, angiotensin receptor blockers, or diuretics, and regularly thereafter 5
• The American College of Cardiology recommends monitoring blood pressure regularly and adjusting treatment as needed to achieve target blood pressure levels, which are <140/85 mmHg for most patients and <130/80 mmHg for patients with diabetes, chronic kidney disease, or established cardiovascular disease 3, 5

Laboratory Testing Recommendations for Initiating Antihypertensive Therapy

Baseline Laboratory Assessment

Follow‑Up Laboratory Monitoring

Monitoring of Potassium with Dietary Changes

Screening for Secondary Hypertension

Management of Asymptomatic Elevated Blood Pressure

Diagnosis Confirmation

• The American College of Cardiology recommends confirming hypertension with out‑of‑office blood pressure measurement (ambulatory or home monitoring) before initiating therapy in adults with office readings of 130‑159 mmHg systolic or 80‑99 mmHg diastolic【11】【12】.
• White‑coat hypertension (elevated office BP but normal out‑of‑office BP in the range 130‑160 mmHg systolic or 80‑100 mmHg diastolic) is associated with minimal cardiovascular risk and should not trigger treatment【11】【12】.
• Masked hypertension (normal office BP but elevated out‑of‑office BP) carries cardiovascular risk comparable to sustained hypertension and warrants pharmacologic therapy【11】【12】.

Cardiovascular Risk Stratification

• The ACC/AHA guideline advises calculating the 10‑year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations【13】.
• Baseline laboratory evaluation should include a basic metabolic panel (creatinine and electrolytes) to assess renal function and electrolyte status【13】.
• Patients with diabetes mellitus or chronic kidney disease are automatically classified as high‑risk for cardiovascular events【13】.

Treatment Algorithms by Blood‑Pressure Stage

Elevated Blood Pressure (SBP 120‑129 mmHg, DBP < 80 mmHg)

• Initiate lifestyle modifications only and reassess in 3‑6 months; repeat annual BP evaluation if the range persists【13】【14】.

Stage 1 Hypertension (SBP 130‑139 mmHg or DBP 80‑89 mmHg)

• If 10‑year ASCVD risk < 10 %: start with lifestyle modifications alone and reassess in 3‑6 months【13】【14】.
• If ASCVD risk ≥ 10 % or diabetes or chronic kidney disease present: begin lifestyle modifications and pharmacologic therapy simultaneously; reassess in 1 month【13】【14】.

Stage 2 Hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg)

• Initiate combination therapy with two antihypertensive agents from different classes together with lifestyle changes; arrange primary‑care evaluation within 1 month and reassess BP in 1 month【13】【14】.

Very High Blood Pressure (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)

• This level does not automatically constitute a hypertensive emergency; immediate assessment for acute target‑organ damage is required【15】.
• If target‑organ damage is present: manage as a hypertensive emergency with ICU admission and intravenous therapy【15】.
• If no target‑organ damage: treat as hypertensive urgency using oral antihypertensives and arrange outpatient follow‑up within 2‑4 weeks【15】.
• Up to one‑third of patients with diastolic BP > 95 mmHg may normalize before follow‑up; rapid BP lowering in asymptomatic patients can be harmful【15】.

First‑Line Pharmacologic Therapy

• Thiazide or thiazide‑like diuretics (chlorthalidone preferred for its longer half‑life and proven cardiovascular benefit) are recommended as initial agents【13】【14】.
• ACE inhibitors or angiotensin‑receptor blockers are preferred in patients with diabetes or chronic kidney disease【13】【14】.
• Dihydropyridine calcium‑channel blockers (e.g., amlodipine) are also first‑line options【13】【14】.
• Combination of an ACE inhibitor with an ARB is not recommended【13】【14】.

Blood‑Pressure Targets

• Aim for <130/80 mmHg in most adults younger than 65 years【13】【14】.
• Aim for systolic <130 mmHg in adults aged 65 years or older【13】【14】.

Monitoring and Follow‑Up

• Check electrolytes and renal function 2‑4 weeks after initiating ACE inhibitors, ARBs, or diuretics【13】【14】.
• Reassess blood pressure monthly until the target is achieved【13】【14】.
• Screen for orthostatic hypotension in older adults or those with postural symptoms【13】.
• Perform annual reassessment for patients whose BP remains within normal limits【13】.

Critical Pitfalls to Avoid

• Do not treat asymptomatic elevated BP in the emergency department without evidence of target‑organ damage, as this may cause hypotension‑related complications【15】.
• Avoid rapid BP reduction in asymptomatic patients; gradual lowering over weeks to months reduces the risk of cerebral, renal, or coronary ischemia【15】.
• Do not assume that all severely elevated BP requires hospitalization; only hypertensive emergencies with organ damage need ICU care【15】.
• Do not overlook white‑coat hypertension; confirm diagnosis with out‑of‑office measurements to prevent unnecessary treatment【11】【12】.

Annual Monitoring and Follow‑up for Adults with Controlled Hypertension on Medication

Routine Annual Evaluation

• The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that adults whose hypertension is controlled on stable medication (target < 130/80 mmHg) receive a formal blood‑pressure assessment once per year. 16

Triggers Requiring Earlier Reassessment

• If a routine visit reveals a blood‑pressure reading above the target, the patient should be reassessed within 1 month rather than waiting for the next annual visit. 16
• The emergence of new symptoms suggestive of target‑organ damage (e.g., chest discomfort, shortness of breath, neurological changes) mandates immediate evaluation, independent of the scheduled monitoring interval. 16
• Any change in antihypertensive medication regimen or dose adjustment requires a follow‑up visit within 1 month to confirm efficacy and tolerability. 16

Monitoring Interval Considerations

• Monitoring intervals should not be extended beyond one year in patients with well‑controlled hypertension, because blood‑pressure control can be affected by weight gain, increased dietary sodium, reduced physical activity, or declining medication adherence. 16

Role of Out‑of‑Office Blood‑Pressure Measurement

• Home blood‑pressure monitoring between annual visits provides valuable data, helps detect white‑coat or masked hypertension, and can inform clinical decisions. 16